Is compounded semaglutide illegal now?

Not categorically — but the routine, mass-market version most patients bought online is no longer permitted. Because the FDA declared the semaglutide shortage resolved (February 21, 2025) and the enforcement-discretion window closed, pharmacies can no longer make copies of the FDA-approved drug at scale. A state-licensed (503A) pharmacy can still compound semaglutide for an individual patient when a prescriber documents a specific clinical reason the approved product will not work — a narrow exception, not a loophole for cheap copies.

Why did my telehealth provider stop offering compounded semaglutide?

Most large telehealth companies exited compounded GLP-1s after the shortage was declared over and the FDA began enforcement. In March 2026 the FDA announced 30 warning letters to telehealth firms over how they marketed these products. Continuing to sell routine compounded copies now carries real legal risk, so many providers stopped rather than face enforcement.

Is compounded semaglutide safe?

Compounded drugs are not FDA-approved, which means the FDA does not review their safety, effectiveness, or quality before they are sold. The FDA has warned about fraudulent products with false label information and unknown sourcing. That is not a claim that every compounded product is dangerous, but you cannot verify quality the way you can with an FDA-approved product. Discuss any compounded medication with a clinician and pharmacist you trust.

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

A 503A pharmacy compounds for one named patient at a time against a specific prescription. A 503B outsourcing facility can make larger batches but is more heavily regulated and may only compound from bulk drug substances that are on the FDA's 503B bulks list or on the drug shortage list. Semaglutide and tirzepatide are currently on neither, which sharply limits 503B compounding of them.

Is Compounded Semaglutide Still Legal? What the 2026 Rules Actually Say

Key Takeaways

The semaglutide shortage was declared resolved on February 21, 2025, and the tirzepatide shortage on December 19, 2024. Once a shortage ends, mass compounding of copies is no longer allowed.
The enforcement-discretion windows have closed — for semaglutide under 503A pharmacies as of April 22, 2025. Routine compounded copies are now outside the rules.
A narrow legal path remains: a 503A pharmacy filling a prescription for one patient when a prescriber documents a real, patient-specific reason the FDA-approved drug will not work (for example, an allergy to an inactive ingredient).
In March 2026 the FDA announced 30 warning letters to telehealth companies over how they marketed compounded GLP-1s — chiefly for implying the products were the “same” as FDA-approved drugs.
Compounded drugs are not FDA-approved, so their safety, effectiveness, and quality are not reviewed before sale. This is general information, not medical or legal advice.

Why this question suddenly matters

For a couple of years, “compounded” semaglutide and tirzepatide were everywhere — advertised by telehealth startups at a fraction of the brand-name price. That was possible because both drugs were in shortage, and federal law gives compounding pharmacies more latitude to make copies of a drug while it is on the FDA’s shortage list.

That window has closed. As the FDA’s own compounding update lays out, the shortages are over, and with them the legal basis for routine compounded copies. Here is what actually changed, with the dates.

What the FDA actually decided, and when

The shortages ended on specific dates:

Tirzepatide (the drug in Zepbound and Mounjaro): the FDA first determined the shortage resolved on October 2, 2024. After litigation prompted a reevaluation, it issued a new decision confirming the shortage resolved on December 19, 2024.
Semaglutide (the drug in Wegovy and Ozempic): the FDA determined the shortage resolved on February 21, 2025.

To avoid abruptly cutting off patients, the FDA gave compounders short grace periods (“enforcement discretion”) before it would act. Those have since ended:

For 503A pharmacies compounding semaglutide, enforcement discretion ran until April 22, 2025. A federal court declined to block the FDA on April 24, 2025, so that window is closed.
For 503A pharmacies compounding tirzepatide, the discretion period ended earlier, in the first quarter of 2025.
For 503B outsourcing facilities, the FDA notes that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on the drug shortage list — which means outsourcing facilities generally cannot compound them either.

Translation: the legal machinery that made cheap, widely advertised compounded copies possible has been switched off.

What is still allowed

Compounding did not become illegal — copying commercially available drugs at scale did. A 503A pharmacy can still compound semaglutide or tirzepatide for an individual patient, but only within real limits:

It must be for a specific patient against a prescription.
It cannot be “essentially a copy” of the FDA-approved drug unless the prescriber determines and documents that the patient needs a change that makes a significant difference for them — for instance, an allergy to an inactive ingredient in the approved product.

The FDA defines “essentially a copy” narrowly. It has said, for example, that combining semaglutide with vitamin B12 does not escape the rule when the ingredients are within about 10% of commercially available strengths and given the same way. It has also stated it does not currently intend to act against a pharmacy that fills four or fewer prescriptions per calendar month of such a copy — a limited discretion, not a green light for volume.

The takeaway for patients: a legitimate compounded prescription now looks like a documented, individualized clinical decision — not a checkout button on a marketing site.

The telehealth crackdown

Much of the recent news comes from the marketing side. On March 3, 2026, the FDA announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products. The main violations were:

Implying “sameness” with FDA-approved products — suggesting a compounded copy is equivalent to Wegovy or Zepbound.
Obscuring where the drug came from — branding products with the telehealth firm’s own name without making clear who actually compounded them.

“Compounded drugs can be important for overcoming shortages or meeting unique patient needs — but compounders should not try to compound drugs in a way that circumvents FDA’s approval process,” said FDA Commissioner Marty Makary. This was the second wave in a broader campaign; the agency says it has sent thousands of letters to pharmaceutical and telehealth firms over the prior six months.

That regulatory pressure is why many well-known telehealth brands quietly stopped offering compounded semaglutide.

Why “not FDA-approved” is the heart of it

The single most important fact for patients is one the FDA repeats: compounded drugs are not FDA-approved. The agency does not review their safety, effectiveness, or quality before they reach you. FDA-approved medications go through a rigorous premarket review; compounded products do not, and they are not the same as generic drugs (which are approved).

The FDA has also flagged outright fraud in this market — products with false information on their labels, sometimes naming pharmacies that do not exist or that never made the product. None of this means every compounded dose is unsafe. It means you cannot verify quality the way you can with an approved product, and that is exactly the protection you give up.

A note on liraglutide

One older GLP-1, liraglutide (Saxenda, Victoza), has had a different supply picture — parts of its supply were still listed as limited in the FDA’s early-2025 status updates. Shortage status can change, so if liraglutide is relevant to you, the current FDA Drug Shortages database is the authoritative source rather than any marketing page.

What to do if you were relying on a compounded version

If your compounded prescription is ending, this is a clinical conversation, not a reason to chase a workaround:

Talk to your prescriber about switching to an FDA-approved option — Wegovy or Zepbound — and about coverage, prior authorization, and manufacturer savings programs.
Be skeptical of any site still selling routine “compounded semaglutide” as identical to the brand-name drug at a steep discount. That is precisely the marketing the FDA is now targeting.
If a compounded product is genuinely appropriate for a documented medical reason, make sure it comes from a licensed pharmacy your clinician knows and can vouch for.

This article is general information about a fast-moving legal situation, not medical or legal advice for your case. For how we source and review this content, see our editorial policy.